Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α

Soon Young Jang, Sung Wuk Jang, Je Sang Ko

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Human estrogen receptor α (ERα) is a nuclear transcription factor that displays a major therapeutic target for breast cancer. The transcriptional activity of ERα can be regulated by particular estrogen receptor modulators. Celastrol, a quinine methide triterpene extracted from a Chinese medicine (Trypterygium wilfordii Hook F.), has been reported to have therapeutic efficacy against various cancer cells, including prostate cancer, leukemia, and melanoma cells. However, ERα regulation by Celastrol has not been reported. In this study, we investigated the effects of Celastrol on the growth of breast cancer cells. We observed that Celastrol decreased expression of ERα at both the mRNA and the protein levels in MCF7 and T47D human breast cancer cells. Results from a luciferase assay showed that Celastrol decreased the transcriptional activity of ERα. Also, Celastrol treatment inhibited ERα target gene expression, including expressions of cyclin D 1, progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells. We propose that Celastrol, an anti-cancer drug extracted from natural sources, induces inhibition of cell growth through modulation of ERα in estrogen positive breast cancer cells and is a candidate for use in cancer chemotherapy for human breast cancer.

Original languageEnglish
Pages (from-to)57-65
Number of pages9
JournalCancer Letters
Volume300
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Estrogen Receptors
Estrogens
Cells
Modulation
Breast Neoplasms
Growth
Cyclin D
Neoplasms
Triterpenes
Estrogen Receptor Modulators
Chemotherapy
Quinine
Hooks
Cell growth
Progesterone Receptors
Cell Cycle Checkpoints
tripterine
Luciferases
Gene expression
Medicine

Keywords

  • Anti-cancer drug
  • Breast cancer
  • Celastrol
  • Estrogen
  • Estrogen receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α. / Jang, Soon Young; Jang, Sung Wuk; Ko, Je Sang.

In: Cancer Letters, Vol. 300, No. 1, 01.01.2011, p. 57-65.

Research output: Contribution to journalArticle

@article{8c37dddcd2df46ab928da49f421cae8a,
title = "Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α",
abstract = "Human estrogen receptor α (ERα) is a nuclear transcription factor that displays a major therapeutic target for breast cancer. The transcriptional activity of ERα can be regulated by particular estrogen receptor modulators. Celastrol, a quinine methide triterpene extracted from a Chinese medicine (Trypterygium wilfordii Hook F.), has been reported to have therapeutic efficacy against various cancer cells, including prostate cancer, leukemia, and melanoma cells. However, ERα regulation by Celastrol has not been reported. In this study, we investigated the effects of Celastrol on the growth of breast cancer cells. We observed that Celastrol decreased expression of ERα at both the mRNA and the protein levels in MCF7 and T47D human breast cancer cells. Results from a luciferase assay showed that Celastrol decreased the transcriptional activity of ERα. Also, Celastrol treatment inhibited ERα target gene expression, including expressions of cyclin D 1, progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells. We propose that Celastrol, an anti-cancer drug extracted from natural sources, induces inhibition of cell growth through modulation of ERα in estrogen positive breast cancer cells and is a candidate for use in cancer chemotherapy for human breast cancer.",
keywords = "Anti-cancer drug, Breast cancer, Celastrol, Estrogen, Estrogen receptor",
author = "Jang, {Soon Young} and Jang, {Sung Wuk} and Ko, {Je Sang}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2010.09.006",
language = "English",
volume = "300",
pages = "57--65",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α

AU - Jang, Soon Young

AU - Jang, Sung Wuk

AU - Ko, Je Sang

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Human estrogen receptor α (ERα) is a nuclear transcription factor that displays a major therapeutic target for breast cancer. The transcriptional activity of ERα can be regulated by particular estrogen receptor modulators. Celastrol, a quinine methide triterpene extracted from a Chinese medicine (Trypterygium wilfordii Hook F.), has been reported to have therapeutic efficacy against various cancer cells, including prostate cancer, leukemia, and melanoma cells. However, ERα regulation by Celastrol has not been reported. In this study, we investigated the effects of Celastrol on the growth of breast cancer cells. We observed that Celastrol decreased expression of ERα at both the mRNA and the protein levels in MCF7 and T47D human breast cancer cells. Results from a luciferase assay showed that Celastrol decreased the transcriptional activity of ERα. Also, Celastrol treatment inhibited ERα target gene expression, including expressions of cyclin D 1, progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells. We propose that Celastrol, an anti-cancer drug extracted from natural sources, induces inhibition of cell growth through modulation of ERα in estrogen positive breast cancer cells and is a candidate for use in cancer chemotherapy for human breast cancer.

AB - Human estrogen receptor α (ERα) is a nuclear transcription factor that displays a major therapeutic target for breast cancer. The transcriptional activity of ERα can be regulated by particular estrogen receptor modulators. Celastrol, a quinine methide triterpene extracted from a Chinese medicine (Trypterygium wilfordii Hook F.), has been reported to have therapeutic efficacy against various cancer cells, including prostate cancer, leukemia, and melanoma cells. However, ERα regulation by Celastrol has not been reported. In this study, we investigated the effects of Celastrol on the growth of breast cancer cells. We observed that Celastrol decreased expression of ERα at both the mRNA and the protein levels in MCF7 and T47D human breast cancer cells. Results from a luciferase assay showed that Celastrol decreased the transcriptional activity of ERα. Also, Celastrol treatment inhibited ERα target gene expression, including expressions of cyclin D 1, progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells. We propose that Celastrol, an anti-cancer drug extracted from natural sources, induces inhibition of cell growth through modulation of ERα in estrogen positive breast cancer cells and is a candidate for use in cancer chemotherapy for human breast cancer.

KW - Anti-cancer drug

KW - Breast cancer

KW - Celastrol

KW - Estrogen

KW - Estrogen receptor

UR - http://www.scopus.com/inward/record.url?scp=78549293218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549293218&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2010.09.006

DO - 10.1016/j.canlet.2010.09.006

M3 - Article

VL - 300

SP - 57

EP - 65

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 1

ER -